Lixte Biotechnology Q1 2025 Earnings Report

Lixte Biotechnology EPS Results

• Actual EPS: -$0.29
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Lixte Biotechnology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lixte Biotechnology Announcement Details

• Quarter: Q1 2025
• Date: 5/12/2025
• Time: Before Market Opens
• Conference Call Date: Monday, May 12, 2025
• Conference Call Time: 8:00AM ET

Lixte Biotechnology (NASDAQ:NMAD) is a clinical-stage biotechnology company focused on developing cancer therapies that target protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, survival and response to treatment. The company’s research is based on the premise that inhibiting PP2A may help make cancer cells more vulnerable to existing therapies.

Lixte’s lead investigational compound is LB-100, a small-molecule PP2A inhibitor being evaluated in combination with other cancer treatments. The company has explored LB-100 in preclinical studies and early-stage clinical trials involving solid tumors and other malignancies. Lixte’s development strategy centers on combining its PP2A-targeting compounds with chemotherapy, radiation, immunotherapy or other targeted treatments.

Founded in 2001, Lixte is headquartered in Pasadena, California. As a clinical-stage company, it focuses primarily on research and development and does not have an established commercial product portfolio. Its programs are directed toward potential applications in oncology, although the safety and effectiveness of its investigational treatments remain subject to clinical testing and regulatory review.